

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106686 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61P 35/00 (2006.01)
A61K 9/08 (2006.01) C12Q 1/6886 (2018.01)

(21) International Application Number:

PCT/US2024/055945

(22) International Filing Date:

14 November 2024 (14.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/599,378 15 November 2023 (15.11.2023) US
63/637,875 23 April 2024 (23.04.2024) US

(71) Applicant: **DAY ONE BIOPHARMACEUTICALS, INC.** [US/US]; 2000 Sierra Point Parkway, Suite 501, Brisbane, California 94005 (US).

(72) Inventors: **BLACKMAN, Samuel C.**; 2000 Sierra Point Parkway, Suite 501, Brisbane, 94005 (US). **CHIODIN, Davy**; 2000 Sierra Point Parkway, Suite 501, Brisbane, California 94005 (US).

(74) Agent: **CHEN, Ying** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94034 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS OF TREATING PEDIATRIC LOW-GRADE GLIOMA




FIG. 5A

(57) Abstract: In one aspect, described herein is a method of treating a relapsed or refractory pediatric low-grade glioma (pLGG) in a subject in need thereof, comprising administering to the subject tovorafenib or a salt thereof, wherein the subject is 6 months of age or older. In some embodiments, the pediatric low-grade glioma (pLGG) harbors a BRAF fusion or rearrangement, or BRAF V600 mutation. In some embodiments, the method comprises administering a starting dose, a reduced dose, and optionally a further reduced dose.

WO 2025/106686 A1